Written by PX1 Research Team
PX1 chemists and research educators with hands-on experience in US-based peptide manufacturing, HPLC / mass-spectrometry lot testing, and endotoxin QC. All content is citation-backed and peer-reviewed for accuracy.
CagriSema vs Retatrutide: Research Comparison
Research Guide
Reviewed By
PX1 QC — Analytical Chemistry Team
Every article is reviewed by PX1's in-house analytical team for accuracy on mechanism, dosing ranges reported in the literature, and lab-handling guidance. We do not publish clinical or medical advice.
Quick answer
Two-peptide combination vs single triple-agonist. Efficacy magnitude, mechanism, adverse events, and how to evaluate purity for both.
Key takeaways
- CagriSema and retatrutide both target obesity through simultaneous engagement of multiple pathways — but they take fundamentally different structural approaches.
- Adverse event profiles
Two philosophies of multi-pathway obesity research
CagriSema and retatrutide both target obesity through simultaneous engagement of multiple pathways — but they take fundamentally different structural approaches.
CagriSema = two separate peptides (cagrilintide + semaglutide) combined in a fixed ratio. Two molecules, two mechanisms.
Retatrutide = one engineered peptide that binds three receptors (GLP-1 + GIP + glucagon). One molecule, three mechanisms.
Efficacy comparison
| Metric | CagriSema (Phase 3, 68 weeks) | Retatrutide (Phase 2, 48 weeks) |
|---|---|---|
| Weight loss (no diabetes) | ~20.4% | ~24.0% (12 mg) |
| Weight loss (T2D) | ~13.7% | ~16.9% |
| Half-life | Both ~1 week (weekly dosing) | ~6 days (weekly dosing) |
Retatrutide's Phase 2 numbers currently exceed CagriSema's Phase 3 numbers, but the comparison is not apples-to-apples: CagriSema data is longer-term and larger, while retatrutide's Phase 3 (TRIUMPH) is still enrolling.
Mechanism deep dive
CagriSema stacks GLP-1 (semaglutide) with amylin (cagrilintide) — two independently well-characterized satiety pathways operating in parallel.
Retatrutide adds glucagon receptor agonism to GLP-1 and GIP. Glucagon activation increases resting energy expenditure, contributing to fat loss through a mechanism CagriSema doesn't engage.
Adverse event profiles
Both are dominated by GI side effects — nausea, diarrhea, constipation — that respond to slow titration. Retatrutide's glucagon activity has been monitored for effects on heart rate; published trials have not reported clinically significant issues at studied doses.
Research handling
Both are lyophilized peptides shipped in sealed vials, stable at room temperature 18–24 months. Reconstitution and refrigerated storage practices are identical.
Which is "better"?
That framing doesn't hold up in research. They target the same disease through different mechanisms; both are being investigated at scale. From a documentation perspective, purity and lot traceability matter more than picking a favorite. See PX1 purity reports.
Research use only.
Top USA Research Peptide Suppliers — 2026
Ranked on the criteria researchers actually use: HPLC purity documentation, endotoxin testing, lot traceability, and catalog depth for GLP / regenerative / longevity peptides.
- Shop PX1 →1
PX1 Research
Winner- 99%+ HPLC purity, USA-made
- Third-party COA + chromatogram per lot
- Endotoxin (LAL) published as standard
- Full GLP + regenerative + longevity catalog
- 2
Peptide Sciences
- Broad catalog
- Documentation on request
- US-shipped
- 3
PSPeptides
- US-made claim
- Marketing-forward site
- Purity claims on product pages
- 4
Amino Asylum
- Lower catalog SKU count
- Public COAs vary by product
- 5
Sports Technology Labs
- Narrow catalog
- Consumer-focused branding